Evidence map›Paper›PMID 35932759›Full record

ArticleJournal of substance abuse treatment2022

Knowledge, attitudes, and behaviors related to the fentanyl-adulterated drug supply among people who use drugs in Oregon.

Kate LaForge, Erin Stack, Sarah Shin, Justine Pope, Jessica E Larsen, Gillian Leichtling, Judith M Leahy, Andrew Seaman, Dan Hoover, Mikaela Byers and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of substance abuse treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Routes of Drug Use Among Drug Overdose Deaths - United States, 2020-2022.MMWR. Morbidity and mortality weekly report · 2024
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Kate LaForgeComagine Health, 650 NE Holladay St # 1700, Portland, OR 97232, United States of America. Electronic address: klaforge@comagine.org.
Erin StackComagine Health, 650 NE Holladay St # 1700, Portland, OR 97232, United States of America.
Sarah ShinComagine Health, 650 NE Holladay St # 1700, Portland, OR 97232, United States of America.
Justine PopeComagine Health, 650 NE Holladay St # 1700, Portland, OR 97232, United States of America.
Jessica E LarsenDepartment of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, United States of America.
Gillian LeichtlingComagine Health, 650 NE Holladay St # 1700, Portland, OR 97232, United States of America.
Judith M LeahyOregon Health Authority, Acute and Communicable Disease Prevention, Public Health Division, Oregon Health Authority, Salem, OR, United States of America.
Andrew SeamanDepartment of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, United States of America; Old Town Clinic/Central City Concern, Portland, OR, United States of America; Better Life Partners, Hanover, NH, United States of America.
Dan HooverDepartment of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, United States of America.
Mikaela ByersHIV Alliance, Eugene, OR, United States of America.
Caiti BarrieDepartment of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, United States of America.
Laura ChisholmOregon Health Authority, Injury, and Violence Prevention Program, Public Health Division, Oregon Health Authority, Portland, OR, United States of America.
P Todd KorthuisDepartment of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, United States of America; Oregon Health & Science University-Portland State University School of Public Health, Portland, OR, United States of America.
Oregon Health & Science University · USOregon Health Authority · USEugene Research Institute · USThe University of Arizona Global Campus · US

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost ExtensionUH3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2019 to 2022
$4.0M
NCATS NIH HHS UL1 TR002369NIDA NIH HHS UG1 DA015815NIDA NIH HHS UH3 DA044831
6 · The paper itself

Abstract

introductionNonpharmaceutical fentanyl has reconfigured the U.S. illicit drug market, contributing to a drastic increase in overdose drug deaths. While illicit fentanyl has subsumed the drug supply in the Northeast and Midwest, it has more recently reached the West. For this study, we explored knowledge, attitudes, and behaviors among people who use drugs in Oregon in the context of the emergence of fentanyl in the drug supply.

methodsWe conducted in-depth interviews by phone with 34 people who use drugs in Oregon from May to June 2021. We used thematic analysis to analyze transcripts and construct themes.

resultsPeople who use drugs knew about fentanyl, expressed doubt that fentanyl could be found in methamphetamine; believed those who were younger or less experienced were at higher risk for harm; and received information about fentanyl from drug dealers, syringe service programs, or peers (other people who use drugs). Preference for fentanyl's presence in drugs like heroin or methamphetamine was mixed. Some felt that their preference was irrelevant since fentanyl was unavoidable. Participants reported engaging in harm reduction practices, including communicating about fentanyl with dealers and peers, testing for fentanyl, using smaller quantities of drugs, switching from injecting to smoking, and using naloxone.

conclusionPeople who use drugs are responding to the rise of fentanyl on the West Coast and are concerned about the increasing uncertainty and hazards of the drug supply. They are willing and motivated to adopt harm reduction behaviors. Harm reduction promotion from syringe service programs and public health agencies is essential to reduce injury and death from nonpharmaceutical fentanyl.

Indexed as

Drug OverdoseMethamphetamineAnalgesics, OpioidFentanylHealth Knowledge, Attitudes, PracticeHumansOregonAnalgesics, OpioidFentanylMethamphetamineFentanylHarm reductionMethamphetamineOpioidsOverdoseQualitative researchSubstance use

Identifiers

PMID35932759
PMCPMC10635798
OpenAlexW4288734748

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.